"Out of sync and overlooked" - Relationship between social jetlag and anxiety in adolescents: Systematic review and meta-analysis.

Sleep Med RevJul 16, 2026 (epub)
Clinical ResearchPsychiatry

Hannah Ravenhall, Alessio Bellato, Sarah Laxhmi Chellappa et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between social jetlag (SJL) and anxiety in adolescents aged 12-18 years. Analyzing data from 12 studies with 235,526 participants, a small association was identified, with increased SJL correlating with more severe anxiety (Fisher's z = 0.0614, p = 0.0011).

Key findings

  • A small association was found between increased SJL and more severe anxiety (Fisher's z = 0.0614).
  • The meta-analysis included data from 12 studies with a total of 235,526 participants.
  • The association was statistically significant with a p-value of 0.0011.

Why it matters

Understanding the link between social jetlag and anxiety can inform interventions aimed at improving sleep patterns in adolescents, potentially enhancing their mental health outcomes.

Source

PubMed · PMID 42480409

Published in Sleep Med Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.